Yes, you can start ARNI in HFpEF, particularly in specific patient subgroups
ARNI (sacubitril-valsartan) is now recommended for HFpEF (or HFnrEF, as termed in the most recent Canadian guidelines), with the strongest evidence supporting its use in patients with lower-range ejection fractions (45-57%), women, and those with elevated natriuretic peptides. 1
Evidence-Based Recommendation
The 2025 Canadian Cardiovascular Society guidelines explicitly include ARNI as a Tier 1 treatment option for heart failure with nonreduced ejection fraction (HFnrEF, which consolidates HFmrEF and HFpEF into LVEF >40%). 1 This represents the most current guideline position and supersedes older recommendations that were more cautious about ARNI use in this population.
Starting Dose and Titration
- Initial dose: 24/26 mg or 49/51 mg twice daily
- Target dose: 97/103 mg twice daily 1
Key Clinical Trial Evidence
The PARAGON-HF trial 2 enrolled 4,822 patients with HF and EF ≥45% and showed:
- The primary composite outcome (HF hospitalization + CV death) narrowly missed statistical significance (rate ratio 0.87,95% CI 0.75-1.01, p=0.06)
- However, important subgroup analyses revealed heterogeneity of treatment effect:
- Greater benefit in patients with lower EF range (45-57%)
- Greater benefit in women
- Reduced total HF hospitalizations (rate ratio 0.85)
- Improved NYHA class (odds ratio 1.45)
- Better preservation of renal function
- Small but significant improvement in quality of life (KCCQ score)
Who Benefits Most?
Based on meta-analysis 3 and subgroup data, ARNI provides the greatest benefit in HFpEF patients with:
- EF in the 45-57% range (lower end of preserved spectrum)
- Female sex
- Elevated systolic blood pressure (predictor of renal outcomes)
- Elevated NT-proBNP or BNP
- Reduced baseline renal function (eGFR predictor of mortality benefit)
- Higher BMI (predictor of CV mortality reduction)
Safety Considerations
Common adverse effects requiring monitoring:
- Symptomatic hypotension (RR 1.54 vs. ACEi/ARB) - most common titration-limiting factor 3, 2
- Angioedema (similar rate to ACEi)
- Lower risk of hyperkalemia compared to ACEi/ARB 2
- Lower risk of worsening renal function compared to valsartan alone 2
Critical Safety Rule
Maintain at least 36 hours washout period when switching from ACEi to ARNI to minimize angioedema risk 4
Practical Implementation Algorithm
- Confirm HFpEF diagnosis: LVEF >40%, elevated natriuretic peptides, structural heart disease
- Assess for favorable characteristics: EF 45-57%, female, elevated BP, elevated NT-proBNP
- Check contraindications: History of angioedema, symptomatic hypotension, pregnancy
- If switching from ACEi: Wait 36 hours minimum
- Start low dose: 24/26 mg or 49/51 mg twice daily based on BP tolerance
- Titrate every 2-4 weeks to target dose 97/103 mg twice daily as tolerated
- Monitor: BP (especially symptomatic hypotension), renal function, potassium
Integration with Other HFpEF Therapies
The Canadian guidelines position ARNI as Tier 1 therapy alongside SGLT2 inhibitors (which have stronger universal evidence in HFpEF). 1 The sequence of initiation should be individualized, but SGLT2i (empagliflozin or dapagliflozin) have more robust outcome data across the entire HFpEF spectrum and may be preferred as first-line therapy, with ARNI added in appropriate phenotypes.
Common Pitfall to Avoid
Don't dismiss ARNI in HFpEF based solely on the PARAGON-HF primary endpoint missing statistical significance. The totality of evidence shows meaningful benefits in specific subgroups, particularly those with EF closer to 45% and women. The 2025 guidelines reflect this nuanced understanding by including ARNI as an evidence-based option. 1